期刊文献+

Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study

在线阅读 下载PDF
导出
摘要 BACKGROUND Helicobacter pylori(H.pylori)infection is a worldwide problem with increasing burden on the health sector due to its increasing rate of resistance.The conventional triple therapy(TT)is becoming obsolete with a high failure rate of eradication,necessitating the need for better alternatives or regimens.AIM To investigate H.pylori eradication rate of TT vs modified bismuth quadruple therapy.METHODS Ninety-two patients with dyspepsia symptoms and positive ^(13)C-urea breath test were randomly assigned to two groups.The first group(control group)was treated for 14 d using standard TT protocol:Esomeprazole(40 mg twice daily),amoxicillin(1 g twice daily)and clarithromycin(500 mg twice daily).On the other hand,the second group was prescribed a 10-d course of modified bismuth quadruple therapy fortified with zinc carnosine:TT in addition to bismuth subcitrate(240 mg twice daily)and zinc carnosine(75 mg twice daily).A repeated 13C-urea breath test was done 4 wk after the completion of the eradication therapy.RESULTS Among the 92 subjects,67.4%were males and 32.6%were females.There were no differences in demographic characteristics(age,body mass index,smoking history,previous antibiotics use and ethnicity)between the modified bismuth quadruple therapy group and TT group.The eradication rate was higher[93.5%(43/46)]in the modified bismuth quadruple therapy group compared to 69.6%(32/46)in the standard TT group(P=0.003).Of the tested predictor variables,only nationality,smoking and therapy type were statistically significant.Besides dizziness,which was recorded in modified bismuth quadruple therapy group,there were no significant differences in side effects between the two groups.CONCLUSION Ten days of modified bismuth quadruple therapy fortified with zinc carnosine is superior to 14 d of conventional TT in eradicating H.pylori infection,with no additional significant adverse events.
出处 《World Journal of Clinical Cases》 SCIE 2022年第1期227-235,共9页 世界临床病例杂志
基金 Synergy Group。
  • 相关文献

参考文献1

二级参考文献30

  • 1Ahmad Shavakhi,Elham Tabesh,Arezoo Yaghoutkar,Houriye Hashemi,Faezeh Tabesh,Mahsa Khodadoostan,Mohammad Minakari,Sara Shavakhi,Ali Gholamrezaei.The Effects of Multistrain Probiotic Compound on Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Placebo‐Controlled Triple‐Blind Study[J]. Helicobacter . 2013 (4)
  • 2Zhen-Hua Wang,Qin-Yan Gao,Jing-Yuan Fang.Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in Helicobacter pylori Eradication Therapy[J]. Journal of Clinical Gastroenterology . 2013 (1)
  • 3Marco Manfredi,Barbara Bizzarri,Roberto Igino Sacchero,Sergio Maccari,Lorenzo Calabrese,Fabio Fabbian,Gian Luigi de’Angelis.Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics?+?Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy[J]. Helicobacter . 2012 (4)
  • 4Sotirios D. Georgopoulos,Elias Xirouchakis,Beatriz Martinez‐Gonzalez,Dionyssios N. Sgouras,Charikleia Spiliadi,Andreas F. Mentis,Fotini Laoudi.Clinical Evaluation of a Ten‐Day Regimen with E someprazole, M etronidazole, A moxicillin, and C larithromycin for the Eradication of H elicobacter pylori in a High Clarithromycin Resistance Area[J]. Helicobacter . 2013 (6)
  • 5Javier Molina–Infante,Marco Romano,Miguel Fernandez–Bermejo,Alessandro Federico,Antonietta G. Gravina,Liliana Pozzati,Elena Garcia–Abadia,Gema Vinagre–Rodriguez,Carmen Martinez–Alcala,Moises Hernandez–Alonso,Agnese Miranda,Maria Rosaria Iovene,Carmen Pazos–Pacheco,Javier P. Gisbert.Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance[J]. Gastroenterology . 2013 (1)
  • 6Luigi Gatta,Nimish Vakil,Dino Vaira,Carmelo Scarpignato.Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy[J]. BMJ . 2013 (aug07 1)
  • 7Javier P. Gisbert,Javier Molina-Infante,Alicia C. Marin,Gemma Vinagre,Jesus Barrio,Adrian Gerald McNicholl.Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection[J]. Scandinavian Journal of Gastroenterology . 2013 (6)
  • 8Nimish Vakil,Dino Vaira.Treatment for H. pylori Infection: New Challenges With Antimicrobial Resistance[J]. Journal of Clinical Gastroenterology . 2013 (5)
  • 9Sotirios Georgopoulos,Vasilios Papastergiou,Elias Xirouchakis,Foteini Laoudi,Philipos Lisgos,Charikleia Spiliadi,Nikitas Papantoniou,Stylianos Karatapanis.Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial[J]. Journal of Clinical Gastroenterology . 2013 (3)
  • 10Ji Hyun Lim,Dong Ho Lee,Chiun Choi,Seong Tae Lee,Nayoung Kim,Sook Hyang Jeong,Jin Wook Kim,Jin Hyeok Hwang,Young Soo Park,Sang Hyub Lee,Cheol Min Shin,Hyun Jin Jo,Eun Sun Jang,In sung Song,Hyun Chae Jung.Clinical Outcomes of Two‐Week Sequential and Concomitant Therapies for Helicobacter pylori Eradication: A Randomized Pilot Study[J]. Helicobacter . 2013 (3)

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部